Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Somatic Comorbidity in Schizophrenia: Some Possible Biological Mechanisms Across the Life Span
Ingrid Dieset, Ole A. Andreassen, Unn K. Haukvik
Schizophrenia Bulletin (2016) Vol. 42, Iss. 6, pp. 1316-1319
Open Access | Times Cited: 95

Showing 1-25 of 95 citing articles:

Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium
Constantinos Constantinides, Laura K. M. Han, Clara Alloza, et al.
Molecular Psychiatry (2022) Vol. 28, Iss. 3, pp. 1201-1209
Open Access | Times Cited: 78
Therapeutic management of atypical antipsychotic‑related metabolic dysfunctions using GLP‑1 receptor agonists: A systematic review
Octavian Vasiliu
Experimental and Therapeutic Medicine (2023) Vol. 26, Iss. 1
Open Access | Times Cited: 39
Childhood maltreatment severity is associated with elevated C-reactive protein and body mass index in adults with schizophrenia and bipolar diagnoses
Monica Aas, Ingrid Dieset, Sigrun Hope, et al.
Brain Behavior and Immunity (2017) Vol. 65, pp. 342-349
Open Access | Times Cited: 79
Effect of GLP‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: a randomized, placebo‐controlled trial
Pelle L. Ishøy, Filip K. Knop, Brian V. Broberg, et al.
Diabetes Obesity and Metabolism (2016) Vol. 19, Iss. 2, pp. 162-171
Open Access | Times Cited: 69
The Missing Link: How Exosomes and miRNAs can Help in Bridging Psychiatry and Molecular Biology in the Context of Depression, Bipolar Disorder and Schizophrenia
С. К. Груздев, А. А. Yakovlev, Т. А. Дружкова, et al.
Cellular and Molecular Neurobiology (2019) Vol. 39, Iss. 6, pp. 729-750
Closed Access | Times Cited: 63
Exploring the Relationship Between Schizophrenia and Cardiovascular Disease: A Genetic Correlation and Multivariable Mendelian Randomization Study
Rada R Veeneman, Jentien M. Vermeulen, Abdel Abdellaoui, et al.
Schizophrenia Bulletin (2021) Vol. 48, Iss. 2, pp. 463-473
Open Access | Times Cited: 51
Inflammation and cognition in severe mental illness: patterns of covariation and subgroups
Linn Sofie Sæther, Thor Ueland, Beathe Haatveit, et al.
Molecular Psychiatry (2022) Vol. 28, Iss. 3, pp. 1284-1292
Open Access | Times Cited: 32
Resting-state high-frequency heart rate variability is related to respiratory frequency in individuals with severe mental illness but not healthy controls
Daniel Quintana, Maja Elstad, Tobias Kaufmann, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 54
Inflammatory markers are altered in severe mental disorders independent of comorbid cardiometabolic disease risk factors
Ragni H. Mørch, Ingrid Dieset, Ann Færden, et al.
Psychological Medicine (2019) Vol. 49, Iss. 10, pp. 1749-1757
Closed Access | Times Cited: 45
Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders
Tomi Kuusimäki, Haidar Al‐Abdulrasul, Samu Kurki, et al.
Movement Disorders (2021) Vol. 36, Iss. 6, pp. 1353-1361
Open Access | Times Cited: 39
Mortality, morbidity and medical resources utilization of patients with schizophrenia: A case-control community-based study
Shay Gur, Shira Weizman, Brendon Stubbs, et al.
Psychiatry Research (2017) Vol. 260, pp. 177-181
Closed Access | Times Cited: 42
Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs—Influence of Smoking Behavior and Inflammation on Pharmacokinetics
Nicole Moschny, Gudrun Hefner, R. Grohmann, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 6, pp. 514-514
Open Access | Times Cited: 32
Family psychoeducation in schizophrenia and schizophrenia related disorder, treatment compliance, and suicidal risk reduction: questions about their relationship from a naturalistic observation
Yann Hodé, R. Padovani, Wydad Hikmat, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 4
No cognitive‐enhancing effect of GLP‐1 receptor agonism in antipsychotic‐treated, obese patients with schizophrenia
Pelle L. Ishøy, Birgitte Fagerlund, Brian V. Broberg, et al.
Acta Psychiatrica Scandinavica (2017) Vol. 136, Iss. 1, pp. 52-62
Closed Access | Times Cited: 38
Erratum: Effect of GLP‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: A randomized, placebo‐controlled trial
Björn H. Ebdrup, Brian V. Broberg, Pelle L. Ishøy, et al.
Diabetes Obesity and Metabolism (2018) Vol. 20, Iss. 5, pp. 1327-1328
Open Access | Times Cited: 34
Limited evidence of association between dysregulated immune marker levels and telomere length in severe mental disorders
Monica Bettina Elkjær Greenwood Ormerod, Thor Ueland, Monica Aas, et al.
Acta Neuropsychiatrica (2025) Vol. 37
Closed Access
Sleep duration and its associated factors in schizophrenia patients: a large-scale cross-sectional survey
Min Dong, Dandan Liao, Wenyan Tan, et al.
BMC Psychiatry (2025) Vol. 25, Iss. 1
Open Access
Cardiovascular comorbidities in Chinese inpatients with schizophrenia spectrum disorders
Zhe Dong, Gang Wu, Hongbing Liu, et al.
Schizophrenia (2025) Vol. 11, Iss. 1
Open Access
Physical illness in schizophrenia and the role of tolerability in antipsychotic selection: an expert consensus with a focus on cariprazine
Alessandro Cuomo, Giovanni B. Forleo, Taieb Ghodhbane, et al.
Annals of General Psychiatry (2025) Vol. 24, Iss. 1
Open Access
Sex differences in schizophrenia spectrum disorders: insights from the DiAPAson study using a data-driven approach
Alessandra Martinelli, Silvia Leone, Cesare M. Baronio, et al.
Social Psychiatry and Psychiatric Epidemiology (2025)
Open Access
Factors associated with direct health care costs in schizophrenia: Results from the FACE-SZ French dataset
Charles Laidi, Amélie Prigent, A. van der Plas, et al.
European Neuropsychopharmacology (2018) Vol. 28, Iss. 1, pp. 24-36
Open Access | Times Cited: 29
Olanzapine, but not haloperidol, exerts pronounced acute metabolic effects in the methylazoxymethanol rat model
Kateřina Horská, Silje Skrede, Jan Kučera, et al.
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 2
Open Access | Times Cited: 3
Integrating Electronic Health Records and Polygenic Risk to Identify Genetically Unrelated Comorbidities of Schizophrenia That May Be Modifiable
Tess Vessels, Nick Strayer, Hyunjoon Lee, et al.
Biological Psychiatry Global Open Science (2024) Vol. 4, Iss. 3, pp. 100297-100297
Open Access | Times Cited: 3
Comorbidity of chronic somatic diseases in patients with psychotic disorders and their influence on 4-year outcomes of integrated care treatment (ACCESS II study)
Martin Lambert, Friederike Ruppelt, Anna-Katharina Siem, et al.
Schizophrenia Research (2017) Vol. 193, pp. 377-383
Closed Access | Times Cited: 27
Immunomodulatory effects of antipsychotic treatment on gene expression in first-episode psychosis
Outi Mantere, Kalevi Trontti, Judit García‐González, et al.
Journal of Psychiatric Research (2018) Vol. 109, pp. 18-26
Closed Access | Times Cited: 24
Page 1 - Next Page

Scroll to top